Trutino Biosciences Patents

Patent portfolio assigned to Trutino Biosciences (verified via public assignee records). Estimated patent count: 1. San Diego pre-clinical immuno-oncology biotech; On-Demand-Cytokine (ODC) protease-activatable IL-2 prodrug platform. Boehringer Ingelheim has a collaboration plus an option-to-acquire agreement (partner/conditional acquirer). Patent: WO2021016599A1 'IL-2 cytokine prodrugs comprising a cleavable linker' filed by Trutino Biosciences (Google Patents). No direct named competitors confirmed via fetched sources.